Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.
about
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerAre phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases.Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews.A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic reviewThe Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer.Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC).Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.Breathing exercises improve post-operative pulmonary function and quality of life in patients with lung cancer: A meta-analysis.Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment.Use of quality checklists and need for disease-specific guidance in economic evaluations: a meta-review.A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.Treatment of lung cancer: will financial issues become a criterion of choice?
P2860
Q28487847-0550CD56-6872-48CF-86C4-B0AEF626F5B8Q30713425-3A0DB61C-113E-4055-A5BC-E0C84A9EB481Q33814897-77227AF7-A59E-4328-AE88-D719335FE3C0Q34727967-EC6EA26F-E052-47DE-BFA4-E739450A0A39Q34742887-2BFA6F86-5161-4090-8580-AE64224E0726Q35429767-EF5AD95A-A8EE-4A0A-A005-3E6DB5992979Q36138536-0E0689F7-D427-4E3B-B53A-DC2A9CC74F49Q36765647-B5FDDF0F-46AA-4B67-9282-298F1D2B6237Q36773467-4A55F79F-4873-410B-A317-08BD34CF00A3Q37022931-E436C20E-DAB8-4CFD-A897-8B8FA6608368Q38109229-D3799C6B-35E9-4C7E-912C-D514A8F33394Q38547506-BAA88F27-3B9F-4DE6-A859-EC83FB83748BQ38598931-1BCCA90E-C460-435B-A374-2AA7C8A2A47CQ45833913-F3717FB5-0BA0-4CD3-8C97-30A079DABC0D
P2860
Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@ast
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@en
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@nl
type
label
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@ast
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@en
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@nl
prefLabel
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@ast
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@en
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@nl
P2093
P2860
P1433
P1476
Cost effectiveness of treatmen ...... g cancer: a systematic review.
@en
P2093
Carin A Uyl-de Groot
Egbert F Smit
Mathilda L Bongers
Veerle M H Coupé
P2860
P356
10.2165/11595000-000000000-00000
P577
2012-01-01T00:00:00Z
P5875
P6179
1039075765